Literature DB >> 1993900

A comparison of axonal and somatodendritic dopamine release using in vivo dialysis.

P W Kalivas1, P Duffy.   

Abstract

The release of endogenous dopamine from the axon terminal field in the nucleus accumbens and from the A10 dopamine cell bodies of conscious rats was measured using intracranial dialysis. Release of dopamine from both areas was calcium-dependent and markedly inhibited by the presence of the D2 agonist, quinpirole, in the dialysis buffer. However, the addition of tetrodotoxin to the buffer produced less of a decrease in dopamine in the A10 region than in the nucleus accumbens. When dopamine release was examined by substituting K+ for Na+ or by adding amphetamine to the buffer, the evoked release was significantly less in the A10 region than in the nucleus accumbens. Likewise, enhanced extracellular dopamine following blockade of reuptake by nomifensine addition to the dialysis buffer was not as great in the A10 region as in the nucleus accumbens. These data argue that, in general, axonal and somatodendritic dopamine release are regulated by similar factors, although somatodendritic release is less influenced by action potential generation and less responsive to some releasing agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993900     DOI: 10.1111/j.1471-4159.1991.tb02015.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  39 in total

1.  Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum.

Authors:  S J Cragg; S A Greenfield
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

2.  Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging.

Authors:  Yin-Ching I Chen; Ji-Kyung Choi; Susan L Andersen; Bruce R Rosen; Bruce G Jenkins
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

3.  Kappa opioid inhibition of somatodendritic dopamine inhibitory postsynaptic currents.

Authors:  Christopher P Ford; Michael J Beckstead; John T Williams
Journal:  J Neurophysiol       Date:  2006-11-22       Impact factor: 2.714

4.  Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area.

Authors:  M J Nirenberg; J Chan; R A Vaughan; G R Uhl; M J Kuhar; V M Pickel
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

5.  Presynaptic regulation of dendrodendritic dopamine transmission.

Authors:  Michael J Beckstead; Christopher P Ford; Paul E M Phillips; John T Williams
Journal:  Eur J Neurosci       Date:  2007-09-06       Impact factor: 3.386

6.  Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location.

Authors:  Christopher P Ford; Gregory P Mark; John T Williams
Journal:  J Neurosci       Date:  2006-03-08       Impact factor: 6.167

7.  Characterization of noradrenaline release in the locus coeruleus of freely moving awake rats by in vivo microdialysis.

Authors:  Begoña Fernández-Pastor; Yolanda Mateo; Sonia Gómez-Urquijo; J Javier Meana
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

8.  Alpha-melanocyte stimulating hormone increases the activity of melanocortin-3 receptor-expressing neurons in the ventral tegmental area.

Authors:  Katherine Stuhrman West; Chunxia Lu; David P Olson; Aaron G Roseberry
Journal:  J Physiol       Date:  2019-05-26       Impact factor: 5.182

Review 9.  The role of D2-autoreceptors in regulating dopamine neuron activity and transmission.

Authors:  C P Ford
Journal:  Neuroscience       Date:  2014-01-23       Impact factor: 3.590

10.  Effects of the local application of 3-PPP and sulpiride enantiomers into the nucleus accumbens or into the ventral tegmental area on rat locomotor activity: evidence for the functional importance of somatodendritic autoreceptors.

Authors:  S Ahlenius
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.